• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

亨廷顿病的基因治疗。

Gene therapy for Huntington's disease.

机构信息

Department of Neurological Sciences, Rush University Medical Center, Chicago, IL, USA.

出版信息

Neurobiol Dis. 2012 Nov;48(2):243-54. doi: 10.1016/j.nbd.2011.12.030. Epub 2011 Dec 24.

DOI:10.1016/j.nbd.2011.12.030
PMID:22222669
Abstract

Huntington's disease (HD) is a neurodegenerative disease for which there is no cure. Therapies that are efficacious in animal models have to date shown benefit for humans. One potential powerful approach is gene therapy. The ideal method of administration of gene therapy has been hotly debated and viral vectors have provided one method of long-term and wide-spread delivery to the brain. Trophic factors to protect cells from degeneration and RNAi to reduce mutant huntingtin (mHtt) protein expression are 2 main classes of compounds that demonstrate benefit in animal models. This review will examine some commonly used adeno-associated viral (AAV) vectors and discuss some therapies that hold promise for HD.

摘要

亨廷顿病(HD)是一种神经退行性疾病,目前尚无治愈方法。在动物模型中有效的治疗方法迄今为止已显示对人类有益。一种潜在的有效方法是基因治疗。基因治疗的理想给药方法一直存在激烈争论,病毒载体为向大脑提供长期和广泛的递药提供了一种方法。营养因子可保护细胞免受变性,RNAi 可减少突变亨廷顿蛋白(mHtt)的表达,这是在动物模型中显示出益处的 2 种主要化合物。本综述将检查一些常用的腺相关病毒(AAV)载体,并讨论一些对 HD 有希望的治疗方法。

相似文献

1
Gene therapy for Huntington's disease.亨廷顿病的基因治疗。
Neurobiol Dis. 2012 Nov;48(2):243-54. doi: 10.1016/j.nbd.2011.12.030. Epub 2011 Dec 24.
2
Ex vivo delivery of GDNF maintains motor function and prevents neuronal loss in a transgenic mouse model of Huntington's disease.外源性给予 GDNF 可维持亨廷顿病转基因小鼠模型的运动功能并防止神经元丢失。
Exp Neurol. 2010 Jul;224(1):155-62. doi: 10.1016/j.expneurol.2010.03.005. Epub 2010 Mar 19.
3
Restoration of cognitive and motor functions by ciliary neurotrophic factor in a primate model of Huntington's disease.睫状神经营养因子对亨廷顿舞蹈病灵长类动物模型认知和运动功能的恢复作用
Hum Gene Ther. 2000 May 20;11(8):1177-87. doi: 10.1089/10430340050015220.
4
Disease Modification Through Trophic Factor Delivery.通过营养因子递送实现疾病修饰
Methods Mol Biol. 2018;1780:525-547. doi: 10.1007/978-1-4939-7825-0_24.
5
Applications of lentiviral vectors for biology and gene therapy of neurological disorders.慢病毒载体在神经系统疾病生物学及基因治疗中的应用
Curr Gene Ther. 2008 Dec;8(6):461-73. doi: 10.2174/156652308786847996.
6
Neuroprotective effect of a CNTF-expressing lentiviral vector in the quinolinic acid rat model of Huntington's disease.表达睫状神经营养因子的慢病毒载体在喹啉酸诱导的大鼠亨廷顿病模型中的神经保护作用
Neurobiol Dis. 2001 Jun;8(3):433-46. doi: 10.1006/nbdi.2001.0388.
7
Protective effect of encapsulated cells producing neurotrophic factor CNTF in a monkey model of Huntington's disease.分泌神经营养因子睫状神经营养因子的包囊化细胞在亨廷顿病猴模型中的保护作用
Nature. 1997 Mar 27;386(6623):395-9. doi: 10.1038/386395a0.
8
Adult neurotrophic factor-secreting stem cells: a potential novel therapy for neurodegenerative diseases.分泌神经营养因子的成体干细胞:一种治疗神经退行性疾病的潜在新疗法。
Isr Med Assoc J. 2009 Apr;11(4):201-4.
9
Neuroprotective gene therapy for Huntington's disease, using polymer-encapsulated cells engineered to secrete human ciliary neurotrophic factor: results of a phase I study.用于亨廷顿舞蹈症的神经保护基因疗法,采用经基因工程改造以分泌人睫状神经营养因子的聚合物包裹细胞:一项I期研究的结果
Hum Gene Ther. 2004 Oct;15(10):968-75. doi: 10.1089/hum.2004.15.968.
10
Cellular delivery of trophic factors for the treatment of Huntington's disease: is neuroprotection possible?用于治疗亨廷顿舞蹈症的营养因子的细胞递送:神经保护是否可行?
Exp Neurol. 1999 Sep;159(1):4-20. doi: 10.1006/exnr.1999.7156.

引用本文的文献

1
Huntington's chorea: emerging fields in therapeutics (Review).亨廷顿舞蹈症:治疗学的新兴领域(综述)
Neurogenetics. 2025 Sep 6;26(1):66. doi: 10.1007/s10048-025-00848-1.
2
Crucial aspects for maintaining rAAV stability.维持 rAAV 稳定性的关键方面。
Sci Rep. 2024 Nov 12;14(1):27685. doi: 10.1038/s41598-024-79369-0.
3
Rescue of BDNF expression by the thalamic parafascicular nucleus with chronic treatment with the mGluR2/3 agonist LY379268 may contribute to the LY379268 rescue of enkephalinergic striatal projection neurons in R6/2 Huntington's disease mice.
通过慢性给予代谢型谷氨酸受体 2/3 激动剂 LY379268 治疗丘脑束旁核,可能有助于挽救 R6/2 亨廷顿病小鼠中脑啡肽能纹状体投射神经元的 BDNF 表达,从而发挥 LY379268 的拯救作用。
Neurosci Lett. 2021 Oct 15;763:136180. doi: 10.1016/j.neulet.2021.136180. Epub 2021 Aug 17.
4
Nanomaterial based drug delivery systems for the treatment of neurodegenerative diseases.基于纳米材料的药物传递系统治疗神经退行性疾病。
Biomater Sci. 2020 Aug 7;8(15):4109-4128. doi: 10.1039/d0bm00809e. Epub 2020 Jul 8.
5
A Combinatorial Cell and Drug Delivery Strategy for Huntington's Disease Using Pharmacologically Active Microcarriers and RNAi Neuronally-Committed Mesenchymal Stromal Cells.一种使用具有药理活性的微载体和RNA干扰神经元定向间充质基质细胞治疗亨廷顿舞蹈病的组合细胞与药物递送策略
Pharmaceutics. 2019 Oct 12;11(10):526. doi: 10.3390/pharmaceutics11100526.
6
Intranasal Administration of Mesenchymal Stem Cells Ameliorates the Abnormal Dopamine Transmission System and Inflammatory Reaction in the R6/2 Mouse Model of Huntington Disease.鼻腔内给予间充质干细胞可改善亨廷顿病 R6/2 小鼠模型中异常的多巴胺传递系统和炎症反应。
Cells. 2019 Jun 15;8(6):595. doi: 10.3390/cells8060595.
7
Characteristics and advantages of adeno-associated virus vector-mediated gene therapy for neurodegenerative diseases.腺相关病毒载体介导的神经退行性疾病基因治疗的特点与优势
Neural Regen Res. 2019 Jun;14(6):931-938. doi: 10.4103/1673-5374.250570.
8
Inhibition of astrocyte FAK-JNK signaling promotes subventricular zone neurogenesis through CNTF.抑制星形胶质细胞 FAK-JNK 信号通路通过 CNTF 促进侧脑室下区神经发生。
Glia. 2018 Nov;66(11):2456-2469. doi: 10.1002/glia.23498.
9
Effect of early embryonic deletion of huntingtin from pyramidal neurons on the development and long-term survival of neurons in cerebral cortex and striatum.早期从大脑皮层和纹状体中的锥体神经元中删除 huntingtin 对神经元发育和长期存活的影响。
Neurobiol Dis. 2018 Mar;111:102-117. doi: 10.1016/j.nbd.2017.12.015. Epub 2017 Dec 21.
10
Genome-editing Technologies for Gene and Cell Therapy.用于基因和细胞治疗的基因组编辑技术
Mol Ther. 2016 Mar;24(3):430-46. doi: 10.1038/mt.2016.10. Epub 2016 Jan 12.